Azithromycin, also known as Zithromax, belongs to the class of medicines known as antibacterials orantibiotics. These medicines kill bacteria (small organisms that can cause infection in humans) or stopbacteria from growing. Patients with weakened immune systems, includingpeople with HIV, tend to have more frequent andmore serious bacterial infections. Azithromycinwas approved by the FDA on June 14, 1996, formany uses, including the prevention and treatmentof Mycobacterium avium complex (MAC) inpersons with advanced HIV infection. It is alsobeing investigated to see how well it works inpreventing other kinds of bacterial infections inpeople with HIV.
In one of the first reported cases of its kind, a 3-week-old infant in critical condition recovered from COVID-19 due to rapid recognition and treatment by physicians from McGovern Medical School at The University of Texas Health Science Center at Houston/
The coronavirus disease (COVID-19) is potentially fatal for vulnerable populations like seniors who over 60 years old, and those with underlying medical conditions, like heart disease, diabetes, and lung disease. Reports show that patients are suffering from heart impairment caused by COVID-19. A new study sheds light on the effect of the novel coronavirus on the heart, causing cardiovascular problems, even in those without underlying heart conditions.
The systemic use of heparin for treating severe coronavirus disease (COVID-19) showed significant improvements in oxygen exchange and overall clinical presentation of patients, as reported by a study from Brazil available on a preprint server medRxiv.
A new review paper published in the preprint open-access journal medRxiv in April 2020 reports that there is not enough evidence to justify the widespread use of the drug hydroxychloroquine (HCQ) in the treatment or prophylaxis of the current COVID-19 illness.
Following the emergence of a novel coronavirus in Wuhan, China, in the last month of 2019, it has spread globally to produce the first pandemic of the 21st century. The virus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has already affected over 2.5 million and killed more than 177,000 people as of April 22, 2020.
The COVID-19 pandemic is still spreading around the world and affecting nearly 2.4 million people, with over 164,000 dead so far. With neither vaccine nor proven therapeutic drug being available so far, the need of the hour is for effective treatment. Now, a new study reports the potential usefulness of a combination of hydroxychloroquine and azithromycin as a treatment in mild cases of COVID-19 infection and urges the need for further evaluation and widespread use if its findings are confirmed.
A new study published in Chemrxiv in April 2020 describes the identification of 64 compounds that could potentially be inhibitors of replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 disease pandemic. The research was carried out using a pharmacophore model of an essential viral enzyme, mining data from the Food and Drug Administration (FDA) database of conformations of approved drugs.
The paper looks at repurposed drugs that might demonstrate efficacy against COVID-19, and if they could be manufactured profitably at very low costs to ensure affordable access to vital treatments for COVID-19 at low prices globally.
Researchers from Intermountain Healthcare and University of Utah Health in Salt Lake City have launched two vital clinical trials to test the effectiveness and safety of two drugs - hydroxychloroquine and azithromycin - to treat patients with COVID-19.
Researchers from Intermountain Healthcare and University of Utah Health in Salt Lake City have launched two vital clinical trials to test the effectiveness and safety of two drugs -hydroxychloroquine (HCQ) and azithromycin - to treat patients with COVID-19 (infection with the novel coronavirus).
Washington University School of Medicine in St. Louis is launching a clinical trial for patients hospitalized with COVID-19 at Barnes-Jewish Hospital.
Chloroquine, hydroxychloroquine and azithromycin are being used to treat and prevent COVID-19 despite weak evidence for effectiveness, and physicians and patients should be aware of the drugs' potentially serious adverse events, states a review in CMAJ.
An American Thoracic Society-led international task force has released a guidance document to help clinicians manage COVID-19 patients in the face of a worldwide pandemic and minimal empirical evidence to guide treatment.
Researchers provide a guideline regarding who should be actually taking antimalarial drugs as prophylaxis to prevent getting COVID-19. They say health professionals who are being exposed to COVID-19 positive patients and those who test positive but are asymptomatic should be taking drugs such as Chloroquine and Hydroxychloroquine. They explain that these populations remain most in need, and because of limited supply, these individuals need to be prioritized.
As some consider treating coronavirus patients with a combination of the malaria drug hydroxychloroquine and the antibiotic azithromycin, cardiologists are advising caution because both medications can increase the risk for dangerous abnormal heart rhythms.
SARS-CoV-2, the virus that causes COVID-19, continues to spread, leading to more than 20,000 deaths worldwide in less than four months. Efforts are progressing to develop a COVID-19 vaccine, but it's still likely 12 to 18 months away.
Doctors who use drugs that target antibiotic-resistant bacteria as a first-line defense against pneumonia should probably reconsider this approach, according to a new study of more than 88,000 veterans hospitalized with the disease.
A new study published in the journal BMJ in February 2020 reports that macrolide or penicillin antibiotic consumption in pregnancy could be linked to several adverse health outcomes in children. These include major malformations, cerebral palsy, attention deficit hyperactivity disorder, and autism spectrum disorder.
According to the Centers for Disease Control and Prevention, chlamydia trachomatis is the most commonly reported sexually transmitted bacterial disease in the U.S., totaling 1.7 million cases in 2017. Rates are highest among teenagers and young adults. Left untreated, chlamydia can cause blindness and sterility.
The American Thoracic Society and the Infectious Diseases Society of America have published an official clinical guideline on the diagnosis and treatment of adults with community acquired pneumonia (CAP) in the ATS's Oct. 1 American Journal of Respiratory and Critical Care Medicine.